Skip to main navigation
LinkedIn Twitter
  • Investors
  • Careers
Outlook Therapeutics, Inc. Logo
  • About
    • Overview
    • Senior Leadership
    • Board of Directors
  • Pipeline
    • ONS-5010 / LYTENAVA™ OVERVIEW
    • ONS-5010 CLINICAL PROGRESS
    • UNMET PATIENT NEEDS
    • REPACKAGED IV BEVACIZUMAB
    • NEW OPHTHALMIC ANTI-VEGF
    • POTENTIAL FIRST-LINE THERAPY
  • News
  • Contact

SEC Filings

Home / Investors / Financial Information / SEC Filings

SEC Filings

Filing date Form Description Filing Group View
Aug 10, 2015 D
Other
 View HTML
0001649989-15-000001.rtf
0001649989-15-000001.pdf

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 52
  • Page 53
  • Page 54
  • Page 55
  • Page 56
  • Page 57
  • Page 58
  • Page 59
  • Current page 60
Displaying 591 - 591 of 591 results
  • Investor Overview
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Other Shareholder Information
  • Financial Information
    • SEC Filings
  • Analyst Coverage
  • News & Events
    • Press Releases
    • Events
    • In the News
    • Presentations
  • Corporate Governance
    • Governance Highlights
    • Board Diversity Disclosure
    • Senior Leadership
    • Board of Directors
    • Committee Composition
  • Information Request
  • Print Page Print Page
  • Email Page Email Page
  • RSS Feeds RSS Feeds
  • Email Alerts Email Alerts
  • Contact IR Contact IR
© 2023 Outlook Therapeutics, Inc.
Privacy Policy | Disclaimer